Sensitive and selective analysis of a wide concentration range of IGFBP7 using a surface plasmon resonance biosensor

Emerging microfluidic devices for cancer cells/biomarkers manipulation and detection

“…Aiming to improve the limit of detection attained with this SPR modality, Chen et al [74] implemented a rolling circle amplification (RCA) process to amplify the SPR signal. With this, VEGF was detected in Tris-buffered saline (TBS) at a [73] breast CA15-3 angular 30 U/ml 0.025 U/ml 1-40 U/ml PBS Chen et al [74] breast VEGF angular-RCA N/A 100 pg/ml 100 pg/ml-1 μg/ml TBS Jang et al [75] lung IGFBP-7 angular N/A 10 ng/ml 10-300 ng/ml PBS Ladd et al [76] colon, ovarian CEA wavelength 1 μg/ml N/A N/A serum Fang et al [77] gastric MG7-Ag wavelength N/A N/A N/A serum Springer et al [78] trophoblastic hCG wavelength ∼μg/ml 10 ng/ml N/A 50% blood plasma Law et al [79] N/A TNF-alpha phase N/A 0.5 ng/ml N/A PBS Ladd et al [80] breast, colon, liver concentration of 100 pg/ml with a linear range from 100 pg/ml to 1 μg/ml. An alternative was introduced by Jang et al [75] who demonstrated an SPR biosensor for the detection of insulin-like growth factor binding protein 7 (IGFBP-7), featuring a limit of detection of 10 ng/ml in PBS and a linear range of 10-300 ng/ml.…”

“…With this, VEGF was detected in Tris‐buffered saline (TBS) at a concentration of 100 pg/ml with a linear range from 100 pg/ml to 1 μg/ml. An alternative was introduced by Jang et al [ 75 ] who demonstrated an SPR biosensor for the detection of insulin‐like growth factor binding protein 7 (IGFBP‐7), featuring a limit of detection of 10 ng/ml in PBS and a linear range of 10–300 ng/ml. For this, the authors employed a mixed self‐assembled monolayer (SAM) in conjunction with a specific receptor on an Au thin film.…”

Advances in Biosensor Technologies for Acute Kidney Injury

“…87 As an example, in order to detect IGFBP7, the SPRbased platform was developed. 88 The gold surface of the sensor was functionalized with anti-IGFBP7 antibodies through mercaptoundecanol (MUO), and DSNHS (S 2 (CH 2 ) 11 COO-(CH 2 ) 2 COO-(N-hydroxysuccinimide)) and protein G immobilization. Before anti-IGFBP7 antibody immobilization, non-specific interactions were minimized through ethanolamine blocking (Figure 5b).…”

“…(b) IGFBP7 detection via SPR-based biosensor is illustrated. Reproduced with permission from ref . Copyright (2014) Elsevier.…”

“…The primary role of IGFBP7 is to regulate the bioavailability via direct low-affinity binding of IGFs, since they have a pleiotropic property in diseases . As an example, in order to detect IGFBP7, the SPR-based platform was developed . The gold surface of the sensor was functionalized with anti-IGFBP7 antibodies through mercaptoundecanol (MUO), and DSNHS (S 2 (CH 2 ) 11 COO­(CH 2 ) 2 COO-( N -hydroxysuccinimide)) and protein G immobilization.…”